Carlisle Companies News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.10.24	Carlisle Companies Inc. Q3 Profit Misses Estimates (RTTNews)
17.10.24	Carlisle To Purchase Plasti-Fab For $259.5 Mln - Quick Facts (RTTNews)
24.07.24	Carlisle Companies Inc. Q2 Profit Increases, Beats Estimates (RTTNews)
01.05.24	Carlisle Companies To Expand Research And Innovation Center In Carlisle, Pennsylvania (RTTNews)
25.04.24	Carlisle Companies Inc. Q1 Profit Increases, beats estimates (RTTNews)
06.02.24	Carlisle Companies Inc. Q4 Profit Increases, beats estimates (RTTNews)
30.01.24	Amphenol To Buy CIT Business From Carlisle In $2.025 Bln Cash Deal (RTTNews)
21.12.23	CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster (PR Newswire)
14.12.23	CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance (PR Newswire)
12.12.23	CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in Peopl... (PR Newswire)
07.12.23	Carlisle Companies Announces Vision 2030 Strategy (RTTNews)
28.11.23	Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults (PR Newswire)
24.11.23	Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment (PR Newswire)
27.10.23	CSL and uniQure Win 2023 Prix Galien USA Award (PR Newswire)
26.10.23	Carlisle Companies Inc. Q3 Profit Increases, beats estimates (RTTNews)
11.10.23	New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines (PR Newswire)
19.09.23	CSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems (PR Newswire)
28.08.23	CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine (PR Newswire)
28.08.23	Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines (PR Newswire)
17.08.23	CSL Appoints Jeffrey Ball as First Chief Sustainability Officer (PR Newswire)
26.07.23	Carlisle Companies Inc. Q2 Profit Decreases, but beats estimates (RTTNews)
17.07.23	CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season (PR Newswire)
20.06.23	CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B (PR Newswire)
15.06.23	Carlisle To Sell Carlisle Fluid Technologies - Quick Facts (RTTNews)
05.06.23	Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure (PR Newswire)
18.05.23	Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus (PR Newswire)
02.05.23	Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis (PR Newswire)
27.04.23	Carlisle Companies Inc. Q1 Profit Decreases, misses estimates (RTTNews)
18.04.23	CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe (PR Newswire)
28.03.23	Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV (PR Newswire)
27.03.23	CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts (PR Newswire)
01.03.23	The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE (PR Newswire)
26.02.23	CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing (PR Newswire)
23.02.23	CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb) (PR Newswire)
21.02.23	Biotech Leader CSL Again Named Among America's Best Employers by Forbes (PR Newswire)
20.02.23	First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission (PR Newswire)
07.02.23	Carlisle Companies Inc. Q4 Profit Increases, beats estimates (RTTNews)
12.12.22	CSL Announces Next CEO & Managing Director (PR Newswire)
12.12.22	CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics (PR Newswire)
10.12.22	CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Tr... (PR Newswire)
22.11.22	U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B (PR Newswire)
02.11.22	Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022 (PR Newswire)
01.11.22	CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology (PR Newswire)
27.10.22	Carlisle Companies Inc. Q3 Profit Increases, beats estimates (RTTNews)
06.10.22	CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine (PR Newswire)
05.10.22	CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates (PR Newswire)
26.09.22	New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems (PR Newswire)
26.09.22	New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates (PR Newswire)
13.09.22	CSL presents new research and development center in Marburg, Germany (PR Newswire)
08.09.22	CSL Plasma Provides Free Flu Vaccines to U.S. Plasma Donors (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Carlisle Companies Inc.

Aktien Top/Flop

Meistgelesene Nachrichten